PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorde… Read more
Market Cap & Net Worth: PENTIXAPHARM HOLDING N AG (PTP)
PENTIXAPHARM HOLDING N AG (XETRA:PTP) has a market capitalization of $47.57 Million (€46.34 Million) as of March 19, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #23728 globally and #2588 in its home market, demonstrating a -5.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PENTIXAPHARM HOLDING N AG's stock price €1.87 by its total outstanding shares 24783048 (24.78 Million).
PENTIXAPHARM HOLDING N AG Market Cap History: 2024 to 2026
PENTIXAPHARM HOLDING N AG's market capitalization history from 2024 to 2026. Data shows change from $75.05 Million to $47.57 Million (-44.81% CAGR).
PENTIXAPHARM HOLDING N AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PENTIXAPHARM HOLDING N AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PTP by Market Capitalization
Companies near PENTIXAPHARM HOLDING N AG in the global market cap rankings as of March 19, 2026.
Key companies related to PENTIXAPHARM HOLDING N AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PENTIXAPHARM HOLDING N AG Historical Marketcap From 2024 to 2026
Between 2024 and today, PENTIXAPHARM HOLDING N AG's market cap moved from $75.05 Million to $ 47.57 Million, with a yearly change of -44.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €47.57 Million | +26.18% |
| 2025 | €37.70 Million | -49.76% |
| 2024 | €75.05 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of PENTIXAPHARM HOLDING N AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.57 Million USD |
| MoneyControl | $47.57 Million USD |
| MarketWatch | $47.57 Million USD |
| marketcap.company | $47.57 Million USD |
| Reuters | $47.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.